Developing new materials to control inflammation in autoimmune diseases
Supramolecular biomaterials for tuning the inflammatory properties of the complement system
This study is exploring new materials that can help manage inflammation in autoimmune diseases like rheumatoid arthritis, aiming to create better and less invasive treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11093943 on NIH RePORTER |
What this research studies
This research investigates innovative supramolecular biomaterials designed to modulate the inflammatory response of the complement system, which plays a crucial role in autoimmune diseases like rheumatoid arthritis. By creating self-assembling nanomaterials that target specific complement proteins, the project aims to enhance the body's immune response in a controlled manner, potentially leading to more effective treatments. The approach differs from traditional monoclonal antibodies by aiming to stabilize and selectively neutralize multiple complement components, addressing the limitations of current therapies. Patients may benefit from a more effective and less invasive treatment option for chronic inflammatory conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases, particularly those experiencing chronic inflammation.
Not a fit: Patients with non-autoimmune inflammatory conditions or those not responding to complement system therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from autoimmune diseases by improving the management of inflammation.
How similar studies have performed: Other research has shown promise in using similar approaches to modulate immune responses, indicating potential for success in this novel application.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Collier, Joel H — Duke University
- Study coordinator: Collier, Joel H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.